Current state and future potential of radiopharmaceutical therapy in breast cancer
- 1Texas Oncology, Baylor University Medical Center, Sarah Cannon Research Institute, 3140 Worth Street, Suite 400, Dallas, TX, 75246, USA; Corresponding author.
- 2Abramson Cancer Center, Department of Radiation Oncology and Department of Radiology, Perelman School of Medicine, University of Pennsylvania, 3400 Civic Center Blvd, Philadelphia, PA, 19104, USA
- 3Hoag Family Cancer Institute, 16105 Sand Canyon Ave Ste 215, Irvine, CA, 92618, USA; Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
Abstract
Radiopharmaceutical therapy has been adopted with success in malignancies such as prostate cancer and neuroendocrine tumors. This approach often combines a diagnostic agent to measure and assess target availability prior to administering a parenteral radiotherapeutic agent against the same target. Emerging evidence and ongoing research suggest that this approach could have a beneficial impact in breast cancer treatment, with a number of different breast cancer-specific or tumor microenvironment targets. There are several agents under investigation, with the majority in early-phase trials. This narrative review will provide a brief introduction to radiopharmaceutical imaging and therapy for breast cancer, discuss emerging therapeutic targets under investigation in breast cancer, and discuss challenges with the implementation of radiopharmaceuticals in breast cancer.
Related
- Loco-regional radiopharmaceutical therapy in breast carcinoma using [177Lu]Lu-microseed implants: Development to proof-of-concept
- The Impact of Assisted Reproduction Technology on Breast Cancer Risk for Women With Infertility: Current Insights and Future Perspectives
- Artificial Intelligence in Breast Imaging and Screening: Current Evidence, Applications, and Future Directions.
- The potential biomarkers of organ transplantation in the era of machine perfusion: Current status, challenges, and future directions
- Adoptive Virus-Specific T Cell Therapy for Viral Infections After Allogeneic Hematopoietic Stem Cell Transplantation: Current Strategies and Future Perspectives
BibTeX
@article{oshaughnessy2026current,
title = {{Current state and future potential of radiopharmaceutical therapy in breast cancer}},
author = {Joyce O'Shaughnessy and Neil K. Taunk and Gary A. Ulaner},
journal = {Breast},
year = {2026},
month = oct,
doi = {10.1016/j.breast.2026.104946},
url = {https://doi.org/10.1016/j.breast.2026.104946},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Current state and future potential of radiopharmaceutical therapy in breast cancer
AU - Joyce O'Shaughnessy
AU - Neil K. Taunk
AU - Gary A. Ulaner
PY - 2026
DA - 2026/10/17
JO - Breast
DO - 10.1016/j.breast.2026.104946
UR - https://doi.org/10.1016/j.breast.2026.104946
AB - Radiopharmaceutical therapy has been adopted with success in malignancies such as prostate cancer and neuroendocrine tumors. This approach often combines a diagnostic agent to measure and assess target availability prior to administering a parenteral radiotherapeutic agent against the same target. Emerging evidence and ongoing research suggest that this approach could have a beneficial impact in breast cancer treatment, with a number of different breast cancer-specific or tumor microenvironment targets. There are several agents under investigation, with the majority in early-phase trials. This narrative review will provide a brief introduction to radiopharmaceutical imaging and therapy for breast cancer, discuss emerging therapeutic targets under investigation in breast cancer, and discuss challenges with the implementation of radiopharmaceuticals in breast cancer.
SN - 1532-3080
SN - 0960-9776
ER -